These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 32762993)

  • 21. Comparison of FACT- and EQ-5D-based utility scores in cancer.
    Pickard AS; Ray S; Ganguli A; Cella D
    Value Health; 2012; 15(2):305-11. PubMed ID: 22433762
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact on the Incremental Cost-Effectiveness Ratio of Using Alternatives to EQ-5D in a Markov Model for Multiple Sclerosis.
    Versteegh M
    Pharmacoeconomics; 2016 Nov; 34(11):1133-1144. PubMed ID: 27282692
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Development of the German version of EQ-5D-Y-5L to measure health-related quality of life in children and adolescents: Identification of response labels and pilot testing].
    Kreimeier S; Greiner W
    Z Evid Fortbild Qual Gesundhwes; 2019 Aug; 144-145():24-34. PubMed ID: 31378708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Review of the Psychometric Performance of Selected Child and Adolescent Preference-Based Measures Used to Produce Utilities for Child and Adolescent Health.
    Rowen D; Keetharuth AD; Poku E; Wong R; Pennington B; Wailoo A
    Value Health; 2021 Mar; 24(3):443-460. PubMed ID: 33641779
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessing the Health-Related Quality of Life of Australian Adolescents: An Empirical Comparison of the Child Health Utility 9D and EQ-5D-Y Instruments.
    Chen G; Flynn T; Stevens K; Brazier J; Huynh E; Sawyer M; Roberts R; Ratcliffe J
    Value Health; 2015 Jun; 18(4):432-8. PubMed ID: 26091597
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mapping to obtain EQ-5D utility values for use in NICE health technology assessments.
    Longworth L; Rowen D
    Value Health; 2013; 16(1):202-10. PubMed ID: 23337232
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis.
    Pickard AS; Gooderham M; Hartz S; Nicolay C
    J Med Econ; 2017 Jan; 20(1):19-27. PubMed ID: 27471948
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessing outcomes for cost-utility analysis in mental health interventions: mapping mental health specific outcome measure GHQ-12 onto EQ-5D-3L.
    Lindkvist M; Feldman I
    Health Qual Life Outcomes; 2016 Sep; 14(1):134. PubMed ID: 27644119
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acceptability of Manufacturer-Proposed Utility Values for NICE Cancer Medicine Appraisals: Analysis of Manufacturers' Information Sources.
    Takada S; Narukawa M
    Int J Technol Assess Health Care; 2022 Mar; 38(1):e25. PubMed ID: 35297362
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Health-related quality of life measured using the EQ-5D-5L: South Australian population norms.
    McCaffrey N; Kaambwa B; Currow DC; Ratcliffe J
    Health Qual Life Outcomes; 2016 Sep; 14(1):133. PubMed ID: 27644755
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-Utility Analysis Using EQ-5D-5L Data: Does How the Utilities Are Derived Matter?
    Yang F; Devlin N; Luo N
    Value Health; 2019 Jan; 22(1):45-49. PubMed ID: 30661633
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Valuation Survey of EQ-5D-Y Based on the International Common Protocol: Development of a Value Set in Japan.
    Shiroiwa T; Ikeda S; Noto S; Fukuda T; Stolk E
    Med Decis Making; 2021 Jul; 41(5):597-606. PubMed ID: 33754886
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An EQ-5D-5L Value Set for Vietnam.
    Mai VQ; Sun S; Minh HV; Luo N; Giang KB; Lindholm L; Sahlen KG
    Qual Life Res; 2020 Jul; 29(7):1923-1933. PubMed ID: 32221805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of generic, condition-specific, and mapped health state utility values for multiple myeloma cancer.
    Rowen D; Young T; Brazier J; Gaugris S
    Value Health; 2012 Dec; 15(8):1059-68. PubMed ID: 23244808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EQ-5D Based Utility Values for Adults with Chronic Obstructive Pulmonary Disease: A Systematic Review, Meta-Analysis, and Meta-Regression.
    Salant N; Mohiuddin S; Zhang Y; Ayiku L; Lokuge K; Jacklin P; Owen L
    COPD; 2024 Dec; 21(1):2385358. PubMed ID: 39081103
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brazilian Valuation of EQ-5D-3L Health States: Results from a Saturation Study.
    Santos M; Cintra MA; Monteiro AL; Santos B; Gusmão-Filho F; Andrade MV; Noronha K; Cruz LN; Camey S; Tura B; Kind P
    Med Decis Making; 2016 Feb; 36(2):253-63. PubMed ID: 26492896
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Health state utilities associated with caring for an individual with cutaneous T-cell lymphoma (CTCL).
    Williams K; Gibson A; McNamara L; Jones T; Lloyd AJ
    J Med Econ; 2020 Oct; 23(10):1142-1150. PubMed ID: 32644862
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preference-based measures to obtain health state utility values for use in economic evaluations with child-based populations: a review and UK-based focus group assessment of patient and parent choices.
    Wolstenholme JL; Bargo D; Wang K; Harnden A; Räisänen U; Abel L
    Qual Life Res; 2018 Jul; 27(7):1769-1780. PubMed ID: 29564713
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of EQ-5D-3L with QLU-C10D in Metastatic Melanoma Using Cost-Utility Analysis.
    Kim H; Cook G; Goodall S; Liew D
    Pharmacoecon Open; 2021 Sep; 5(3):459-467. PubMed ID: 33891268
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparing and transforming PROMIS utility values to the EQ-5D.
    Hartman JD; Craig BM
    Qual Life Res; 2018 Mar; 27(3):725-733. PubMed ID: 29264776
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.